Why the study?
Does pharmacologic therapy (nicardipine, nitroprusside, verapamil) improve flow in STEMI patients with no-reflow phenomenon following PCI?
Does pharmacologic therapy (nicardipine, nitroprusside, verapamil) improve flow in STEMI patients with no-reflow phenomenon following PCI?
Nicardipine, nitroprusside, and verapamil are equally effective in treating no-reflow during STEMI PCI, a condition that otherwise carries a poor prognosis.
Answers are grounded in this paper and cite their sources.
Supports equal efficacy of these agents for no-reflow; leaves open confirmation by randomized trials in STEMI PCI.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rezkalla et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: